Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

S. Kusumoto, L. Arcaini, X. Hong, J. Jin, W.S. Kim, Y.L. Kwong, M.G. Peters, Y. Tanaka, A.D. Zelenetz, H. Kuriki, G. Fingerle-Rowson, T. Nielsen, E. Ueda, H. Piper-Lepoutre, G. Sellam, K. Tobinai

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)137-146
Number of pages10
JournalBlood
Volume133
Issue number2
DOIs
Publication statusPublished - 2019

Cite this

Kusumoto, S., Arcaini, L., Hong, X., Jin, J., Kim, W. S., Kwong, Y. L., Peters, M. G., Tanaka, Y., Zelenetz, A. D., Kuriki, H., Fingerle-Rowson, G., Nielsen, T., Ueda, E., Piper-Lepoutre, H., Sellam, G., & Tobinai, K. (2019). Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood, 133(2), 137-146. https://doi.org/10.1182/blood-2018-04-848044